Perspective Therapeutics Inc
Perspective Therapeutics Inc (CATX) Covered Calls
Perspective Therapeutics Inc trades in the Medical Devices industry with an IV Rank of 88.10%, high versus the past year. CATX's highest covered call setup is the $2.50 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 165.96% out of the money with 63 days to expiration, a 171.28% return until expiration, and a 992.32% theoretical annualized return. Across the setups shown, annualized returns run from 992.32% to 992.32% at strikes between $2.50 and $2.50, with 63 to 63 days to expiration, as of Nov 13, 2026.
Read more
Running CATX covered calls helps you generate income from Perspective Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CATX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CATX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CATX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CATX covered call is worth writing.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc.
| 2027-01-15 | 63 | 2.50 | 165.96 | 0.05 | 0.20 | 161.00 | 171.28 | 992.32 | -5.32 | +0.32 | 1,047 | 0.15 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV Rank88.10% High
- Market cap (M$)114
- 52 weeks high-84.74%
- 52 weeks low20.51%
- Analyst recommendationStrong Buy
1.27 - Target price$9.15
873.40% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E—
- EPS (ttm)-1.25
- EPS growth next 5 years13.26%
As of Nov 13, 2026